Abstract:Background: Cholestasis is characterized by intrahepatic accumulation of bile acids (BAs), resulting in liver injury, fibrosis, and liver failure. To date, only ursodeoxycholic and obeticholic acids have been approved for the treatment of cholestasis. As fluorofenidone (AKF-PD) was previously reported to play significant anti-fibrotic and anti-inflammatory roles in various diseases, we investigated whether AKF-PD ameliorates cholestasis. Methods: A mouse model of cholestasis was constructed by administering a 0.1% 3,5-diethoxycarbonyl-1,4-dihydroxychollidine (DDC) diet for 14 days. Male C57BL/6J mice were treated with either AKF-PD or pirfenidone (PD) orally in addition to the DDC diet. Serum and liver tissues were subsequently collected and analyzed. Findings: We found that AKF-PD significantly reduced the levels of serum ALT, AST, and TBA, as well as hepatic BA levels. Hepatic histological analyses demonstrated that AKF-PD markedly attenuated hepatic inflammation and fibrosis. Further preliminarily mechanistic analyses revealed that AKF-PD markedly inhibited expression of Cyp7a1, an enzyme key to BA synthesis, by increasing FXR nuclear translocation, and decreased hepatic inflammation by attenuating Erk/Egr-1-mediated cytokine and chemokine expression. Moreover, AKF-PD was found to substantially reduce liver fibrosis via inhibition of TGFβ1 expression in our mouse model. Interpretation: Here, we found that AKF-PD effectively attenuates cholestasis and hepatic fibrosis in a mouse model of DDC-induced cholestasis. As such, AKF-PD warrants further investigation as a candidate drug for treatment of cholestasis. Funding The National Natural Science Foundation of China; the Outstanding Youth Science Foundation of Chongqing; the Project of Chongqing Universities Innovation Research Group.Declaration of Interest: The authors declare no competing interests.Ethical Approval: All animal experiments were approved by the animal care and use committees at the Medical Research Center (Southwest Hospital, Chongqing, China; the approvednumber: AMUWEC20223018).

Fluorofenidone Attenuates Hepatic Fibrosis By Suppressing The Proliferation And Activation Of Hepatic Stellate Cells

The Antihepatic Fibrotic Effects of Fluorofenidone Via Mapk Signalling Pathways

Fluorofenidone Affects Hepatic Stellate Cell Activation in Hepatic Fibrosis by Targeting the TGF-β1/Smad and MAPK Signaling Pathways.

Fluorofenidone Protects Liver Against Inflammation and Fibrosis by Blocking the Activation of NF‐κB Pathway

Fluorofenidone alleviates liver fibrosis by inhibiting hepatic stellate cell autophagy via the TGF-β1/Smad pathway: implications for liver cancer

Fluorofenidone attenuates renal fibrosis by inhibiting the mtROS-NLRP3 pathway in a murine model of folic acid nephropathy

Fluorofenidone attenuates vascular remodeling in hypoxia-induced pulmonary hypertension of rats.

Fluorofenidone alleviates liver fibrosis by inhibiting hepatic stellate cell autophagy<i> via</i> the TGF-(31/Smad pathway: implications for liver cancer

Fluorofenidone Attenuates Renal Interstitial Fibrosis by Enhancing Autophagy and Retaining Mitochondrial Function

Fluorofenidone Ameliorates Cholestasis and Fibrosis by Inhibiting Hepatic Erk/-Egr-1 Signaling and Tgfβ1/Smad Pathway in Mice.

Fluorofenidone Attenuates Tubulointerstitial Fibrosis by Inhibiting TGF-β1-Induced Fibroblast Activation

Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin‑mediated NLRP3 inflammasome activation

Fluorofenidone Attenuates Inflammation by Inhibiting the NF-кB Pathway.

Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice

Fluorofenidone protects against acute liver failure in mice by regulating MKK4/JNK pathway

Fluorofenidone Attenuates Oxidative Stress and Renal Fibrosis in Obstructive Nephropathy Via Blocking NOX2 (gp91phox) Expression and Inhibiting ERK/MAPK Signaling Pathway

Fluorofenidone is an Effective Drug for Cholestasis and Fibrosis in a Preclinical Study

Fluorofenidone Inhibits UUO/IRI-Induced Renal Fibrosis by Reducing Mitochondrial Damage

Fluorofenidone Inhibits Nicotinamide Adeninedinucleotide Phosphate Oxidase Via PI3K/Akt Pathway in the Pathogenesis of Renal Interstitial Fibrosis

Fluorofenidone Attenuates Collagen I and Transforming Growth Factor‐β1 Expression Through a Nicotinamide Adenine Dinucleotide Phosphate Oxidase‐dependent Way in NRK‐52E Cells

Fluorofenidone Inhibits Macrophage IL-1β Production by Suppressing Inflammasome Activity